- Scancell Holdings said new study data indicated a second vaccine for its so-called Moditope platform could induce cancer tumour rejection.

Pre-clinical datas for the Modi-2 vaccine treatment induced highly potent T cell responses and increased survival in murine models.

Moditope represented a new class of potent and selective immunotherapy agents that could have a profound effect on the way that cancer immunotherapies are developed, the company said.

Modi-2 was currently in pre-clinical development and work was underway to characterise specific homocitrullinated peptides for clinical development with the potential to address different cancer indications to Modi-1, including tumours with a particularly immunosuppressive environment.

The Modi-2 peptide family was the subject of new intellectual property applications.

'We are pleased to be able to provide an update on the progress of our second Moditope vaccine, Modi-2,' chief scientific officer Lindy Durrant said.

'The data clearly demonstrates the potential of homocitrullinated, as well as citrullinated, tumour-associated peptide epitopes to be developed for the treatment of solid cancers.'

At 9:17am: [LON:SCLP] Scancell Holdings PLC share price was +0.25p at 8p

Story provided by